IS
ISCO.US International Stem Cell Corp
- Market cap
- USD 1.28M
- P/E
- -
- P/B
- 1.56x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ISCO.US undervalued?
Graham numberThe Graham number of International Stem Cell Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
International Stem Cell Corp fundamental analysis
No fundamental analysis for International Stem Cell Corp yet.
International Stem Cell Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About International Stem Cell Corp
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company offers anti-aging skin care products, including …
Full company profileInternational Stem Cell Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
International Stem Cell Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.17M | 7.46M | 11.1M | 9.47M | 7.13M | 7.18M | 8.18M | 7.79M | 9.09M | 9.10M | 9.98M |
| Gross Profit | 5.22M | 5.33M | 7.02M | 5.54M | 4.35M | 4.24M | 4.91M | 4.61M | 5.32M | 5.07M | 5.64M |
| Operating Income | -4.85M | -4.94M | -3.47M | -5.73M | -2.82M | -1.92M | -183K | -663K | -68.0K | -267K | -450K |
| EBITDA | - | -5.68M | -1.78M | -3.90M | -2.36M | -509K | 22.0K | 202K | 142K | -48.0K | -322K |
| Net Income | -1.08M | -6.07M | -2.13M | -4.27M | -2.72M | -899K | -331K | -131K | -209K | -418K | -582K |
| EPS | -0.27 | -1.00 | -0.31 | -0.57 | -0.36 | -0.11 | -0.04 | -0.02 | -0.03 | -0.05 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 7.05M | 6.86M | 7.80M | 6.62M | 5.29M | 4.95M | 5.14M | 5.39M | 5.17M | 4.82M | 5.06M |
| Total Liabilities | 3.60M | 4.80M | 5.26M | 9.51M | 5.32M | 9.53M | 9.66M | 9.58M | 9.10M | 8.88M | 9.28M |
| Shareholders' Equity | 3.44M | 2.06M | 2.54M | -2.89M | -33.0K | -4.59M | -4.52M | -4.19M | -3.93M | -4.06M | -4.23M |
| Cash & Short-term Investments | 110K | 304K | 1.08M | 484K | 689K | 171K | 742K | 1.59M | 1.23M | 993K | 1.09M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.20M | -2.14M | -1.08M | -1.40M | -341K | -1.30M | 332K | 929K | 13.0K | 8.00K | 576K |
| Capital Expenditure | 944K | 112K | 185K | 164K | 28.0K | 23.0K | 11.0K | 83.0K | 171K | 45.0K | 84.0K |
| Free Cash Flow | - | -3.01M | -1.74M | -1.89M | -449K | -1.34M | 321K | 846K | -158K | -37.0K | 492K |
| Ratios | |||||||||||
| ROE | -31.3% | -294.0% | -84.0% | - | - | - | - | - | - | - | - |
| ROA | -15.3% | -88.4% | -27.3% | -64.4% | -51.5% | -18.2% | -6.4% | -2.4% | -4.0% | -8.7% | -11.5% |
| Net Profit Margin | -15.1% | -81.4% | -19.2% | -45.0% | -38.2% | -12.5% | -4.0% | -1.7% | -2.3% | -4.6% | -5.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
International Stem Cell Corp dividends
International Stem Cell Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:150 on Jul 29, 2015.
Who owns International Stem Cell Corp
- Insiders 51.54%
- Institutions 0.00%
- Public & others 48.46%
- Shares outstanding 8.00M
- Free float 3.91M
International Stem Cell Corp company profile
- Company name
- International Stem Cell Corp
- Ticker
- ISCO.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 9745 Businesspark Avenue, San Diego, CA, United States, 92131
- Phone
- 760 940 6383
- Website
- internationalstemcell.com
About International Stem Cell Corp
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It serves professional and retail customers. The company was founded in 2001 and is headquartered in San Diego, California.
International Stem Cell Corp management
2- Dr. Andrey Semechkin Ph.D.Co-Chairman of the Board & CEO · born 1960
- Dr. Russell Kern Ph.D.Executive VP, Chief Scientific Officer, Principal Financial Officer & Director · born 1986